Association between ABO blood groups and clinical manifestations and outcomes of COVID-19: a retrospective cross-sectional study in southeast Iran Authors: Sadegh Valinejad Bolghan, Nastaran Mirabutalebi, Fatemeh Khalili, Mahdieh Ardaneh, Kiavash Hushmandi, Rasoul Raesi, Salman Daneshi Published: 2026 ABSTRACT AbstractBlood groups significantly influence individuals’ immune responses and the severity of diseases. This study examined the association between ABO blood groups and clinical features, comorbidities, and outcomes in COVID-19 patients in southeast Iran. This retrospective cross-sectional study included 894 RT-PCR–confirmed COVID-19 patients admitted to two referral hospitals in southeast Iran (April–September 2020). Medical records were reviewed for demographic data, ABO blood groups, clinical features, comorbidities, and outcomes. Disease severity was classified using NIH criteria. Chi-square, Kruskal–Wallis, and multivariable logistic regression (adjusted for age, sex, and comorbidities) were used for analysis. The mean age was 37.36 ± 14.63 years, and 53.1% were female. The mean number of symptoms varied significantly across ABO blood groups (P = 0.014), with group AB showing the lowest values. Hospitalization rates also differed (P = 0.003), being highest in group O. Significant associations were observed between blood groups and fever/chills, cough, rhinorrhea, headache, and gastrointestinal symptoms (all P < 0.05). Comorbidities were more frequent in group O (P = 0.005), particularly cardiovascular disease (P = 0.037). Blood group AB remained independently associated with fewer symptoms after adjustment (aOR = 0.68, 95% CI 0.47–0.98). ABO blood groups were associated with clinical presentation and comorbidities in COVID-19 patients. Blood group O showed higher rates of comorbidities and hospitalization, while blood group AB had a milder symptom profile.Keywords: COVID-19, ABO blood groups, SARS-CoV-2, Symptom severity, Comorbidities, PandemicSubject terms: Diseases, Health care, Medical research, Risk factors Introduction Much work has been done since the beginning of the COVID-19 pandemic, triggered by the SARS-CoV-2 virus, to identify factors that might make some people more susceptible to infection and/or worse affected by the disease. One such factor that has come under scrutiny is the association of ABO blood group with different infections and diseases. This has also been studied in the context of SARS-CoV-2. Multiple worldwide studies have found a link between COVID-19 and ABO blood types. These studies have shown a trend of lower susceptibility to SARS-CoV-2 among people who are blood group O, and higher susceptibility among people who are blood group A1–3. The susceptibility, severity and mortality of COVID-19 have also been studied in ABO blood groups. But this interaction is seldom reported here. Hence, in this retrospective study, we aimed to determine which blood group is more common among COVID-19 patients in Southeast of Iran and its association with the severity and progression of the disease in these patients. This pattern presents interesting questions regarding the biological mechanisms of these associations and their implications for the public health strategies. There are new reports that blood type may be a risk factor for severe COVID-19 with differences in COVID-19 infection, intubation, and mortality rates across ABO and Rh blood groups4. Likewise, a study of COVID-19 patients in Spain revealed that there were statistically significant differences between the frequency of post-COVID complications in the various ABO blood groups, with the group B having a higher incidence of fatigue, myalgia and other complications5. Additionally, a large-scale study identified that people with blood group O and Rh-negative blood were slightly less likely to be infected with SARS-CoV-2 and experience severe COVID-19 symptoms, which underscores the possibility of blood groups affecting outcomes of COVID-196. Furthermore, a worldwide study based on WHO and Johns Hopkins University data revealed that the distribution of ABO blood groups was linked to the dynamics of the COVID-19 pandemic, such that blood group A was associated with increased infection and mortality5. In addition, a multicenter study showed that critically ill COVID-19 patients who had blood group A or AB had higher risks of mechanical ventilation, continuous renal replacement therapy and longer ICU stays than those who had blood group O or B6. A review of the literature studying the correlation between ABO blood type and COVID-19 outcomes, however, revealed that most studies have serious methodological limitations and there is no evidence that ABO blood type is a reliable predictor of COVID-19 risk or severity7. Moreover, a retrospective study in Colorado did not show any correlation between blood type and COVID-19 incidence or severity, even when ethnicity was taken into account to account for the differences in blood type prevalence8. Furthermore, one study in Croatia revealed that the blood group A was significantly more prevalent in COVID-19 patients admitted to the hospital. However, in contrast, blood group O was less common, further reinforcing the link between the blood group ABO and the severity of COVID-199. Another study conducted in Saudi Arabia revealed that those with blood group O were at a reduced risk of being positive for COVID-19. Blood group B, on the other hand, raised the infection risk further emphasizing the possible association of blood group type with susceptibility to COVID-19 infection1. There are many studies around the world that have studied the correlation between ABO blood group and susceptibility and severity of COVID-19, but the results have been inconsistent. Studies conducted so far have concentrated on the risk of infection or mortality, but few have examined the specific clinical characteristics and comorbidities. In addition, data from the Middle Eastern region, particularly Iran, are few. Hence, the current study aimed to fill this gap by assessing the association between ABO blood groups and clinical symptoms, underlying health conditions, severity, and clinical outcomes of COVID-19 among patients with COVID-19 in the southeast region of Iran. Since this study is of a cross-sectional retrospective nature, it was not intended to establish cause/effect or predictive relationships. Material and methods Study design A Cross-Sectional (Descriptive-Analytical) study was performed in two well-known medical centers in the south of Iran. The study began after the approval by the institutional ethics committee which ensured the ethical standard of the study involving human subjects. The data were collected during 6 months, beginning in April 2020, when the COVID-19 pandemic was in its initial phase. Study population A total of 894 patients who were laboratory confirmed to have SARS-CoV-2 infection by real-time polymerase chain reaction (RT-PCR) testing of nasopharyngeal swab samples were included in the study. The analysis included all eligible patients that fulfilled the inclusion criteria during the study period. The patients were divided into three groups based on the severity of their COVID-19 symptoms; Disease severity was retrospectively classified based on the severity criteria of the National Institutes of Health (NIH) and World Health Organization (WHO) for COVID-1910–12. Mild disease was considered as infection without pneumonia or hypoxia. Moderate disease was defined as patients who had clinical and/or radiological evidence of lower respiratory tract involvement and who had oxygen saturations (SpO2) ≥ 94% on room air. Severe disease was defined as SpO2 < 94% on room air, respiratory rate > 30 breaths/min, lung infiltrates involving > 50% of the lung field or need for intensive care unit (ICU) admission and/or mechanical ventilation. The severity was classified on the basis of clinical and radiological data from patients’ records. Inclusion and exclusion criteria Patients who had confirmed COVID-19 infection (positive RT-PCR) and had a complete medical record (including ABO blood group) were included. Patients who did not have sufficient clinical information, unknown blood group status, hematological disorders that interfere with blood typing, or patients with duplicate records were excluded. Data collection All enrolled patients’ clinical and laboratory data were systematically retrieved by reviewing the medical records. The following was involved in the data collection: Demographic Data: Age, sex, and other pertinent demographic data were collected for context. Blood Group Classification: ABO blood group (A, B, AB, O) and Rhesus (Rh) factor (positive or negative) were recorded and analyzed for possible correlation with severity of COVID-19. Clinical Parameters: Clinical parameters including initial clinical symptoms, laboratory investigations (including complete blood count and inflammatory markers), treatment interventions, and clinical outcome were carefully recorded and used to provide a detailed analysis of the severity of the disease. The main aim of this study was to evaluate the prevalence and severity of SARS-CoV-2 infection in various ABO blood groups and Rh factors. In addition, the study sought to identify if certain blood types or Rh factors were risk factors for COVID-19 infection and/or worse disease outcomes. Statistical analysis Using multivariable logistic regression, the independent link of ABO blood groups with important outcomes (≤ 2 or > 2 symptoms, hospitalization, presence of specific symptoms) was studied. O was the reference blood group. Adjustments were made for age (continuous), sex, and underlying comorbidities (cardiovascular disease, hypertension, diabetes, and kidney disease). Odds ratios (aOR) with 95% confidence intervals are presented. The Hosmer–Lemeshow test was used to evaluate model fit. A p value < 0.05 was deemed to be statistically significant. Because of the exploratory nature of this study, all eligible patients over the study period were analyzed to increase the statistical power and precision of the estimates. Results A total of 894 patients with RT-PCR-confirmed COVID-19 were included in this study. The mean age of the participants was 37.36 ± 14.63 years, and 475 (53.1%) were female. In total, 259 (29.0%) patients presented with at least one underlying comorbidity and 180 patients (20.1%) were hospitalized. Clinical symptoms The most common initial symptoms in 894 COVID-19 patients were fever and chills (415; 46.4%), myalgia (337; 37.7%) and headache (327; 36.6%). Other symptoms that were relatively common were fatigue and physical weakness (27.4%), cough (34.1%) and sore throat (21.3%). Other less common symptoms included gastrointestinal problems (9.6%), smell (8.2%) and taste (6.7%) disorders and abnormal chest CT (7.0%). Fever and chills were the most common presenting symptoms as seen in Fig. 1. Prevalence of initial clinical symptoms among 894 COVID-19 patients. Distribution of initial clinical manifestations among patients with COVID-19 (N = 894). Fever and chills were the most frequently reported symptoms (46.4%), followed by myalgia (37.7%) and headache (36.6%). Symptoms analysed statistically according to blood group The mean number of clinical symptoms varied significantly between the ABO blood groups (Kruskal–Wallis test, P = 0.014), and the patients in blood group AB had the lowest mean number of symptoms (2.42 ± 1.92) (Table 1). There was also a significant difference in the hospitalization rates between the blood groups (Chi-square test, P = 0.003) with blood group O having the highest rate (26.5%). There were significant differences among the ABO blood groups in the prevalence of fever and chills (P = 0.008), cough (P = 0.001), rhinorrhea (P = 0.009), headache (P = 0.021), and gastrointestinal symptoms (P = 0.021). Table 1Frequency of clinical symptoms and hospitalization rates according to ABO blood groups in patients with COVID-19 (N = 894).VariableTotal N (%) or Mean (SD)A (n = 241)B (n = 206)AB (n = 104)O (n = 343)P valueNumber of clinical symptoms2.88 (2.02)3.01 (2.20)2.81 (1.97)2.42 (1.92)3.00 (1.87)0.014*Hospitalization180 (20.1)40 (16.6)32 (15.5)17 (16.3)91 (26.5)0.003**Fever and chills415 (46.4)114 (47.3)85 (41.3)37 (35.6)179 (52.2)0.008Cough305 (34.1)97 (40.2)78 (37.9)40 (38.5)90 (26.2)0.001Shortness of breath153 (17.1)35 (14.5)36 (17.5)19 (18.3)63 (18.4)0.651Rhinorrhea116 (13.0)47 (19.5)21 (10.2)11 (10.6)37 (10.8)0.009Fatigue and physical weakness245 (27.4)66 (27.4)52 (25.2)27 (26.0)100 (29.2)0.772Chest pain63 (7.0)16 (6.6)12 (5.8)10 (9.6)25 (7.3)0.657Myalgia337 (37.7)96 (39.8)81 (39.3)27 (26.0)133 (38.8)0.073Headache327 (36.6)94 (39.0)82 (39.8)24 (23.1)127 (37.0)0.021Sore throat190 (21.3)56 (23.2)43 (20.9)17 (16.3)74 (21.6)0.552Joint pain141 (15.8)37 (15.4)27 (13.1)11 (10.6)66 (19.2)0.096Smell disorder73 (8.2)14 (5.8)22 (10.7)9 (8.7)28 (8.2)0.314Taste disorder60 (6.7)11 (4.6)14 (6.8)9 (8.7)26 (7.6)0.421Gastrointestinal symptoms86 (9.6)20 (8.3)13 (6.3)7 (6.7)46 (13.4)0.021Abnormal chest CT findings63 (7.0)21 (8.7)14 (6.8)6 (5.8)22 (6.4)0.636* Kruskal–Wallis test ** Chi-square test. Frequency of clinical symptoms and hospitalization rates according to ABO blood groups in patients with COVID-19 (N = 894). * Kruskal–Wallis test ** Chi-square test. Underlying comorbidities There was also significant difference in the overall prevalence of underlying comorbidities across the ABO blood groups (P = 0.005) with the highest prevalence in blood group O, which also had significantly higher prevalence of cardiovascular diseases (P = 0.037) (Table 2). Table 2Prevalence of underlying comorbidities according to ABO blood groups in COVID-19 patients (N = 894).VariableTotal N (%)A (n = 241)B (n = 206)AB (n = 104)O (n = 343)P valueUnderlying disease259 (29.0)70 (29.0)58 (28.2)29 (27.9)102 (29.7)0.005*Cardiovascular disease34 (3.8)8 (3.3)5 (2.4)4 (3.8)17 (5.0)0.037Hypertension32 (3.6)9 (3.7)8 (3.9)5 (4.8)10 (2.9)0.394Diabetes mellitus46 (5.1)12 (5.0)10 (4.9)6 (5.8)18 (5.2)0.816Kidney disease22 (2.5)5 (2.1)4 (1.9)3 (2.9)10 (2.9)0.161* Chi-square test. Prevalence of underlying comorbidities according to ABO blood groups in COVID-19 patients (N = 894). * Chi-square test. Clinical outcomes and disease severity The clinical results of ABO blood groups are shown in Table 3. There was no significant difference in recovery rates among the blood groups (P = 0.227). The number of deaths (n = 9) was too small to identify significant differences in mortality and no definitive conclusions can be drawn about this outcome. Table 3Clinical outcomes of COVID-19 patients according to ABO blood groups (N = 894).OutcomeTotal N (%)A (n = 241)B (n = 206)AB (n = 104)O (n = 343)P valueRecovery267 (29.9)77 (32.0)62 (30.1)29 (27.9)99 (28.9)0.227Hospitalization180 (20.1)40 (16.6)32 (15.5)17 (16.3)91 (26.5)0.003Death9 (1.0)3 (1.2)1 (0.5)1 (1.0)4 (1.2)-Home quarantine551 (61.6)147 (61.0)135 (65.5)66 (63.5)203 (59.2)0.312 Clinical outcomes of COVID-19 patients according to ABO blood groups (N = 894). Diseases severity according to NIH/WHO criteria Patients were categorized according to NIH and WHO criteria into mild, moderate and severe. The distribution of severity by ABO blood groups did not show any statistical difference (P = 0.124), as demonstrated in Table 4. The proportion of severe cases was numerically higher for blood group O, however. Table 4Distribution of COVID-19 severity categories according to ABO blood groups (N = 894).Severity categoryTotal N (%)A (n = 241)B (n = 206)AB (n = 104)O (n = 343)P value*Mild512 (57.3)148 (61.4)124 (60.2)65 (62.5)175 (51.0)0.124Moderate269 (30.1)68 (28.2)59 (28.6)28 (26.9)114 (33.2)Severe113 (12.6)25 (10.4)23 (11.2)11 (10.6)54 (15.7)* Chi-square test. Distribution of COVID-19 severity categories according to ABO blood groups (N = 894). * Chi-square test. Multivariate analysis Blood group AB was found to be independently associated with reduced odds of having more than 2 clinical symptoms after adjusting for age, sex and underlying comorbidities (aOR = 0.68, 95% CI 0.47–0.98, P = 0.038). This was a weak association (aOR = 1.49; 95% CI 0.98–2.26; P = 0.062) after adjustment. There were still significant associations with fever/chills and cough after adjustment (Table 5). All models were adjusted for age, sex and for the major comorbidities. The model fit was acceptable (Hosmer–Lemeshow test P > 0.05). Table 5Multivariable logistic regression analysis of ABO blood groups with key COVID-19 outcomes (Reference: Blood group O).Outcome variableBlood groupaOR95% CIP value > 2 Clinical symptoms (vs ≤ 2)A1.120.81–1.550.492B0.940.67–1.320.724AB0.680.47–0.980.038HospitalizationA0.780.52–1.170.231B0.710.46–1.100.124AB0.850.49–1.470.562Fever and chillsA0.890.65–1.220.472B0.760.54–1.060.104AB0.620.41–0.940.025CoughA1.681.18–2.390.004B1.551.07–2.240.020AB1.621.02–2.570.041Gastrointestinal symptomsA0.680.42–1.100.118B0.610.36–1.030.065AB0.590.31–1.120.106 Multivariable logistic regression analysis of ABO blood groups with key COVID-19 outcomes (Reference: Blood group O). Discussion The purpose of this study was to investigate the clinical characteristics of COVID-19 in various blood groups in 894 patients infected with the virus. The results of this study were that there were differences in the number of clinical symptoms, prevalence of clinical symptoms and underlying health conditions. The variation in the number of clinical symptoms among the blood groups showed that those with blood group AB had the least symptoms than other blood groups. This difference was statistically significant and indicates a clinical symptom presentation that is different for this blood group. The results of this study were similar to other studies that were done in the same area13–15. The link between ABO blood groups and clinical features of COVID-19 could be attributed to several biological mechanisms. Previous studies have indicated that anti-A antibodies may affect the binding of SARS-CoV-2 spike protein to angiotensin-converting enzyme 2 (ACE2) receptors, which may limit viral attachment and entry into cells in blood group O individuals16. Furthermore, ABO blood groups have been linked to variations in inflammatory response, endothelial activation, von Willebrand factor, coagulation pathways and thrombotic susceptibility, which can lead to different severity and outcomes of COVID-1914,15,17. The results of our study showed that different blood groups did not have a statistically significant difference in abnormal chest CT findings, and this finding is consistent with other studies18,19. There have also been some studies that indicate that the blood group has no effect on the incidence of clinical symptoms of the disease20–22. The prevalence of underlying diseases was the highest in the blood group O and the lowest in group AB. This difference could be the main reason for the difference in severity of COVID-19 disease in these groups. This is in line with the findings of other studies and many reports have validated blood type O as a blood type that is susceptible to a number of diseases23–26. In our study, there was no significant difference in the prevalence of hypertension in various blood groups. But group O was unique among the other groups with the highest prevalence of heart disease. The results obtained are in line with those of other studies27,28. The findings of the present study did not reveal any statistically significant difference in clinical outcomes of COVID-19 (recovery, hospitalization and mortality) between ABO blood groups. Because of the small number of deaths (n = 9), however, the study was highly underpowered to detect any possible differences in mortality. Thus, there is no definite evidence to draw a firm conclusion on the association between ABO blood group and the risk of mortality. The results are similar to those of several other studies17,29,30. This was a contrary finding to several studies31–33. More studies on the effect of blood groups on symptoms of COVID-19 are suggested. This may be used to find out which blood groups are more or less susceptible to this disease. After adjusting for age, sex and comorbidities in the multivariate analysis, most associations were still seen, although the effect size was somewhat reduced. The associations between ABO blood groups and clinical manifestations observed should be taken with a pinch of salt because of the study’s observational design. This may be attributed to residual confounding and population specific factors. Limitations There are some limitations to this study. The first is that the study design is retrospective cross sectional, which makes it difficult to draw causal conclusions between ABO blood groups and severity of COVID-19. Second, the study was done in one geographic area of Iran, which may restrict the generalizability of the results to the other population. Third, there were some potentially confounding factors, such as body mass index, smoking, vaccination status, socioeconomic status and viral variants, which were not recorded in the medical records. Fourth, selection bias and information bias may have occurred as the data were obtained from retrospective hospital records. Finally, multivariable analyses were carried out, but residual confounding cannot be ruled out. Conclusion This current study revealed that there were significant variations in the clinical presentations and comorbidities between the ABO blood groups of COVID-19 patients. Underlying diseases and hospitalization rates seemed to be higher in blood group O than in blood group AB, which appeared to be associated with less severe symptoms. The small number of events did not allow for any meaningful conclusions to be drawn in relation to mortality. The results of this study need to be viewed with caution because the study was observational and the statistical power for rare events like death was low. Acknowledgements The researchers express their gratitude to the staff of Statistics and Information Technology Management at Jiroft University of Medical Sciences for their assistance with researchers in data gathering. This paper was financially supported by the Vice chancellor for Research and Technology, Jiroft University of Medical Sciences. Author contributions S.V.B., N.M., F.K., and M.A. contributed to conceptualization, methodology, and data analysis. M.A. collected data. R.R. conducted the literature review and prepared the text of the manuscript. K.H. performed the statistical analysis, interpreted the results, and prepared the figures. R.R., K.H., S.D., M.A., and S.V.B. critically reviewed the manuscript. R.R., and S.D. supervised the entire project. Funding This research was done with the financial support of Jiroft University of Medical Sciences. Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Ethical approval and consent to participate This study was approved by the Biomedical Research Ethics Committee of Jiroft University of Medical Sciences (IR.JMU.REC.1403.037). Written informed consent was obtained from all participants or their legal guardians (where applicable) prior to data collection. The study was conducted in accordance with the ethical standards of the institutional and national research committees and the principles of the 1975 Declaration of Helsinki and its later amendments. Patient confidentiality was strictly maintained by anonymizing all data during analysis. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Rasoul Raesi, Email: Raesi.br881@gmail.com. Salman Daneshi, Email: salmandaneshi008@gmail.com. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.